PuSH - Publikationsserver des Helmholtz Zentrums München

Freibothe, I.* ; Müller, T.D.

Inkretine als Grundlage der Adipositastherapie.

Incretins as the basis of obesity treatment.

Innere Med., DOI: 10.1007/s00108-025-01893-6 (2025)
Postprint DOI PMC
Obesity represents an immense challenge for patients and physicians due to its numerous comorbidities and complications. For a long time, safe and effective pharmacological treatment remained wishful thinking. Bariatric surgery was considered the only option for sustained weight loss; however, with the advent of incretin-based treatment, initially introduced as a highly effective component of anti-diabetic treatment, research began to focus on the complex gastroenteropancreatic endocrine system, including central hunger and satiety regulation. This shift was driven by the discovery of a remarkable side effect: placebo-controlled weight reduction. Subsequent groundbreaking pharmacological developments based on long-acting peptides, the administration of which could be reduced from twice daily in earlier forms of treatment to once weekly, now enables significant weight reduction of over 20%, with a tolerable safety profile. This article provides an illustrative overview of the corresponding associations and highlights this milestone in obesity treatment.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Appetite Regulation ; Glucagon-like Peptide 1 (glp-1) ; Glucose-dependent Insulinotropic Polypeptide (gip) ; Obesity/drug Therapy ; Weight Loss; Appetite
ISSN (print) / ISBN 2731-7080
e-ISSN 2731-7099
Zeitschrift Innere Medizin
Verlag Springer
Verlagsort Heidelbergerplatz 3, Berlin, Germany
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)